Skip to content

A Phase 1 Study of S-892216 (COVID-19)

A Phase 1 Study of S-892216 in Healthy Adults (COVID-19)

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2031230082
Enrollment
347
Registered
2023-05-20
Start date
2023-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Sponsors

Gomez Juan Carlos
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Common in all parts -Apparently healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead ECG at screening and on admission. Or, determined to be eligible for participation by the investigator or subinvestigator in consideration of the safety in case for participants with clinical laboratory test results beyond the upper limit or below the lower limit of the reference range of the study site. -Male and female -Capable of giving signed informed consent as described in this protocol which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Only for part 1, 2, and 4 -Participant must be 18 to 55 years of age inclusive, at the time of signing the ICF. -A person with Japanese parents. -Body Mass Index (BMI) >= 18.5 and = 18.5 and = 18.5 and = 40 kg. Only for Part 6, 7, and 8 -Participants must be 18 to 55 years of age inclusive, at the time of signing the ICF. -A person with Japanese parents. -Body Mass Index (BMI) >= 18.5 and = 70 kg. Only for Part 9 -Participants must be 18 to 45 years of age inclusive, at the time of signing the ICF. -Female -A person with Japanese parents. -Body Mass Index (BMI) >= 18.5 and = 40 kg.

Exclusion criteria

Exclusion criteria: Common in all parts -History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders that may significantly alter the absorption, metabolism, or elimination of drugs; determined to constitute a risk when administering the study intervention or to interfere with the interpretation of data. -In C-SSRS examined at screeing or on admission, 'Yes' to questions regarding suicidal ideation 1 to 5, or to questions regarding unintended self-injury behavior out of suicidal behavior, or judged as having risks for suicide in the opinion of the investigator (Part 1-5). -At screeing or on admission, The total score of 10 points or more in PHQ-9 (Part 1-5).

Design outcomes

Primary

MeasureTime frame
Adverse events, physical examination, laboratory tests, vital signs, 12-lead ECG, holter ECG, Columbia-Suicide Severity Rating Scale (C-SSRS), Patient Health Questionnaire-9 (PHQ-9), Pharmacokinetics parameters

Contacts

Public ContactCorporate Communications Department

Shionogi & Co., Ltd.

shionogiclintrials-admin@shionogi.co.jp+81-6-6209-7885

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026